1. Urinary Prostaglandin E2 Metabolite and Pancreatic Cancer Risk: Case-Control Study in Urban Shanghai.
- Author
-
Zhao, Jing, Wang, Jing, Du, Jinfeng, Xu, Hongli, Zhang, Wei, Ni, Quan-Xing, Yu, Herbert, Risch, Harvey A., Gao, Yu-Tang, and Gao, Ying
- Subjects
- *
RISK factors of pancreatic cancer , *DINOPROSTONE , *METABOLITES , *ETIOLOGY of diseases , *CYCLOOXYGENASE 2 , *CASE-control method - Abstract
Pancreatic cancer has been increasing in importance in Shanghai over the last four decades. The etiology of the disease is still unclear. Evidence suggests that the COX-2 pathway, an important component of inflammation, may be involved in the disease. We aimed to evaluate the association between urinary prostaglandin E2 metabolite (PGE-M) level and risk of pancreatic cancer. From a recent population-based case-control study in Shanghai, 200 pancreatic ductal adenocarcinoma cases and 200 gender- and age- frequency matched controls were selected for the present analysis. Urinary PGE-M was measured with a liquid chromatography/mass spectrometric assay. Adjusted unconditional logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs). A positive association was observed between PGE-M leve and pancreatic cancer risk: OR = 1.63 (95% CI 1.01–2.63) for the third tertile compared to the first. Though the interactions were not statistically significant, the associations tended to be stronger among subjects with diabetes history (OR = 3.32; 95% CI 1.20–9.19) and higher meat intake (OR = 2.12; 95% CI 1.10–4.06). The result suggests that higher urinary PGE-M level may be associated with increased risk of pancreatic ductal adenocarcinoma. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF